Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Inventory (2018 - 2025)

Historic Inventory for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $751346.0.

  • China SXT Pharmaceuticals' Inventory fell 1336.28% to $751346.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $751346.0, marking a year-over-year decrease of 1336.28%. This contributed to the annual value of $828053.0 for FY2025, which is 417.66% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Inventory of $751346.0 as of Q3 2025, which was down 1336.28% from $828053.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Inventory high stood at $1.0 million for Q1 2022, and its period low was $493214.0 during Q3 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' median Inventory value was $811454.0 (recorded in 2024), while the average stood at $760881.1.
  • Its Inventory has fluctuated over the past 5 years, first plummeted by 4778.97% in 2023, then soared by 7583.3% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Inventory (Quarter) stood at $837447.0 in 2021, then dropped by 24.99% to $628186.0 in 2022, then fell by 21.49% to $493214.0 in 2023, then surged by 75.83% to $867233.0 in 2024, then fell by 13.36% to $751346.0 in 2025.
  • Its Inventory stands at $751346.0 for Q3 2025, versus $828053.0 for Q1 2025 and $867233.0 for Q3 2024.